TY - JOUR
T1 - Associations between the gut microbiome and fatigue in cancer patients
AU - Hajjar, Joud
AU - Mendoza, Tito
AU - Zhang, Liangliang
AU - Fu, Siqing
AU - Piha-Paul, Sarina A.
AU - Hong, David S.
AU - Janku, Filip
AU - Karp, Daniel D.
AU - Ballhausen, Alexej
AU - Gong, Jing
AU - Zarifa, Abdulrazzak
AU - Peterson, Christine B.
AU - Meric-Bernstam, Funda
AU - Jenq, Robert
AU - Naing, Aung
N1 - Funding Information:
Support provided, in part, by the Biostatistics Resource Group and the Assessment, Intervention and Measurement (AIM) Shared Resource through a Cancer Center Support Grant (CA16672, PI: P. Pisters, MD Anderson Cancer Center) and by Clinical Translational Science Award 1UL1 TR003167. TM was supported by NIH/NCI R01CA242565.
Funding Information:
JH reports research support from Immune Deficiency Foundation, Jeffery Modell Foundation and Chao Physician-Scientist, and Baxalta and has served on an advisory board for Takeda, CSL, Behring, Horizon, and Pharming, outside the submitted work; SF reports clinical trial research support from AstraZeneca, Abbisko, Anaeropharma Science, Arrien Pharmaceuticals, BeiGene, BioAtla, LLC, Boehringer Ingelheim, Eli Lilly, Hooki-pia Biotech, Huya Bioscience International, IMV, Inc., Innovent Biologics, Co., Ltd., Lyvgen Biopharm, Co., Ltd., MacroGenics, Medivir AB, Millennium Pharmaceuticals, Inc., Nerviano Medical Sciences, NeuPharma, Inc., NIH/NCI, Novartis, OncoMed Pharmaceuticals, Parexel International, LLC, Sellas Life Sciences Group, Soricimed Biopharma, Inc., Tolero Pharmaceuticals, outside the submitted work, grants from NIH/NCI; SAP-P reports grants from AbbVie, Inc., ABM Therapeutics, Inc., Acepodia, Inc., Alkermes, Inc., Aminex Therapeutics, Amphivena Therapeutics, Inc., BioMarin Pharmaceutical, Inc. , Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical Co., Daichi Sankyo, Inc., Eli Lilly, Five Prime Therapeutics, Genmab A/S, GlaxoSmith-Kline, Helix BioPharma Corp., Incyte Corp., Jacobio Pharmaceuticals Co., Ltd, Medimmune, LLC, Medivation, Inc., Merck Sharp and Dohme Corp., Novartis Pharmaceuticals, Pieris Pharmaceuticals, Inc., Pfizer, Principia Biopharma, Inc., Puma Biotechnology, Inc., Rapt Therapeutics, Inc., Seattle Genetics, Taiho Oncology, Tesaro, Inc., Transthera Bio, and NCI/NIH Core Grant, outside the submitted work; DSH reports research/grant funding from Abbvie, Adaptimmune, Amgen, Astra-Zeneca, BMS, Daiichi-Sankyo, Eisai, Fate Therapeutics, Genmab, Ignyta, Kite, Kyowa, Lilly, Medimmune, Merck, Merrimack, Mirati, MIRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfizer; personal fees from Axiom, Baxter, GLG, Group H, Guidepoint Global, Jannsen, Medscape, Numab, Trieza Therapetics; research/grant funding and personal fees from Bayer, Genentech, Infinity, LOXO, Seattle Genetics, Takeda; and other from Molecular Match, OncoResponse, Presagia Inc, during the conduct of the study; FJ reports grants and research funding from Novartis, Genentech, BioMed Valley Discoveries, Plexxikon, Piqur, Symphogen, Bayer, and Fujifilm Corporation, Astex, Asana, Astellas, Agios, Proximagen, Bristol-Myers Sqibb, and Upsher-Smith Laboratories, research funding & SAB from Deciphera, SAB from IFM Therapeutics, Synlogic, Gaurdant Health, Ideaya, and PureTech Health, and services as paid consultant & ownership interests in Trovagene, and paid consultant in Immunomet, Sotio, and Jazz Pharmaceuticals, outside the submitted work; FM-B reports grants from Aileron, AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Guardant Health Inc., Millennium Pharmaceuticals, Novartis, Taiho Pharmaceutical Co.; personal fees for advisory from Seattle Genetics Inc., Immunomedics, Inflection Biosciences, Mersana Therapeutics, Silverback Therapeutics, Spectrum Pharmaceuticals, Zentalis; personal fees from Aduro, BioTech Inc, Alkermes, F. Hoffman-La Roche Ltd, IBM Watson, Jackson Laboratory, Kolon Life Science, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Samsung Bioepis, Tyra Biosciences, Xencor, Zymeworks; personal fees for travel related from Beth Israel Deaconess Medical Center, grants and personal fees for Consulting from Genentech, Debio, and eFFECTOR Therapeutics; personal fees for consulting and advisory committee from Seattle Genetics Inc., personal fees for advisory and grants Puma Biotechnology Inc.; grants from Chugai Biopharmaceuticals, Mayo Clinic, and Rutgers Cancer Institute of New Jersey outside the submitted work; RJ reports personal fees from Kaleido Biosciences, Seres Therapeutics, Merck, Prolacta Bioscience, MaaT Pharma, MicroBiomeDX, Karius, Ziopharm Oncology, and holds a patent with Seres Therapeutics, outside the submitted work; AN reports research support and non-financial support from Merck Sharp & Dohme Corp., grants from NCI/NIH, research support from The University of Texas MD Anderson Cancer Center, during the conduct of the study; grants from NCI, research support from EMD Serono, MedIm-mune, Healios Onc. Nutrition, Atterocor, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera BioSciences, TopAlliance BioSciences, Eli Lilly, Kymab, Arcus, and PsiOxus, A non-financial support for travel and accommodation from ARMO BioSciences, and has served as an advisory board member for Novartis, Kymab, Genome & Company, and CytomX Therapeutics outside the submitted work. TM, LZ, DDK, AB, JG, AZ, CP declare no competing interests.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Fatigue is the most prevalent symptom of cancer and its treatments. Changes in the intestinal microbiome have been identified in chronic fatigue syndrome and other neuropsychiatric disorders, and cancer patients. However, the association between intestinal microbiome and fatigue in patients with advanced cancers has not been evaluated. Understanding the connection between intestinal microbiome and fatigue will provide interventional and therapeutic opportunities to manipulate the microbiome to improve fatigue and other patients’ reported outcomes. In this project, we aimed to identify associations between microbiome composition and fatigue in advanced cancer patients. In this cross-sectional observational study at a tertiary cancer care center, we included 88 patients with advanced, metastatic, unresectable cancers who were in a washout period from chemotherapy. We measured fatigue using the MD Anderson Symptom Inventory—Immunotherapy fatigue score, and used 16srRNA to analyze intestinal microbiome. Using correlation analysis we found that Eubacterium hallii was negatively associated with fatigue severity scores (r = − 0.30, p = 0.005), whereas Cosenzaea was positively associated with fatigue scores (r = 0.33, p = 0.0002). We identified microbial species that exhibit distinct composition between high-fatigued and low-fatigued cancer patients. Further studies are warranted to investigate whether modulating the microbiome reduces cancer patients’ fatigue severity and improves their quality of life.
AB - Fatigue is the most prevalent symptom of cancer and its treatments. Changes in the intestinal microbiome have been identified in chronic fatigue syndrome and other neuropsychiatric disorders, and cancer patients. However, the association between intestinal microbiome and fatigue in patients with advanced cancers has not been evaluated. Understanding the connection between intestinal microbiome and fatigue will provide interventional and therapeutic opportunities to manipulate the microbiome to improve fatigue and other patients’ reported outcomes. In this project, we aimed to identify associations between microbiome composition and fatigue in advanced cancer patients. In this cross-sectional observational study at a tertiary cancer care center, we included 88 patients with advanced, metastatic, unresectable cancers who were in a washout period from chemotherapy. We measured fatigue using the MD Anderson Symptom Inventory—Immunotherapy fatigue score, and used 16srRNA to analyze intestinal microbiome. Using correlation analysis we found that Eubacterium hallii was negatively associated with fatigue severity scores (r = − 0.30, p = 0.005), whereas Cosenzaea was positively associated with fatigue scores (r = 0.33, p = 0.0002). We identified microbial species that exhibit distinct composition between high-fatigued and low-fatigued cancer patients. Further studies are warranted to investigate whether modulating the microbiome reduces cancer patients’ fatigue severity and improves their quality of life.
UR - http://www.scopus.com/inward/record.url?scp=85102494154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102494154&partnerID=8YFLogxK
U2 - 10.1038/s41598-021-84783-9
DO - 10.1038/s41598-021-84783-9
M3 - Article
C2 - 33712647
AN - SCOPUS:85102494154
SN - 2045-2322
VL - 11
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 5847
ER -